The document reviews HCA Holdings, Inc.'s Q4 2013 earnings, highlighting solid results despite challenging volume conditions. Key points include a 6.7% YoY EBITDA growth, improved surgical trends, and a conservative 2014 guidance. The impact of the Affordable Care Act (ACA) on HCA's financials is discussed, with an expected benefit of 1-2% of EBITDA. The document reiterates a Buy rating with a $58 price target for HCA.
doj/DataSet10/EFTA01452941.pdf
{"title":"Q4'2013 Earnings Review for HCA Holdings, Inc.","key_people":["Deutsche Bank Securities Inc."],"document_date":"2014-02-04","document_type":"financial","key_organizations":["HCA Holdings, Inc.","Deutsche Bank Securities Inc."]}